Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5215499

NC(=O)c1ccc2c(c1)N(C(=O)COCc1ccccc1)CC2.NCc1cccc(C(=O)N(CC(=O)O)c2ccccc2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.38
FOLH1 Q04609 2/20 0.36
F2 P00734 3/20 0.35
F10 P00742 1/20 0.35
ROCK1 Q13464 2/20 0.35
MAPT P10636 3/20 0.34
ALDH1A1 P00352 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
NOTUM Q6P988 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
GRM5 P41594 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7430442 0.96 RIPK1 (0.38) RIPK1FOLH1F2F10ROCK1
Trifluoroacetic Acid SCHEMBL5208180 0.91 RIPK1 (0.42) RIPK1FOLH1F2F10ROCK1
Trifluoroacetic Acid SCHEMBL5212450 0.91 RIPK1 (0.39) RIPK1FOLH1F2F10ROCK1
Trifluoroacetic Acid SCHEMBL5210860 0.90 RIPK1 (0.42) RIPK1FOLH1F2F10ROCK1
Trifluoroacetic Acid SCHEMBL5211441 0.90 RIPK1 (0.38) RIPK1F2F10ROCK1ALDH1A1
Trifluoroacetic Acid SCHEMBL5215547 0.88 RIPK1 (0.36) RIPK1F2F10ROCK1NPC1
Trifluoroacetic Acid SCHEMBL5210720 0.88 HSD17B3 (0.38) RIPK1MAPTALDH1A1
Trifluoroacetic Acid SCHEMBL5210137 0.88 RIPK1 (0.37) RIPK1F2F10ROCK1ALDH1A1
Trifluoroacetic Acid SCHEMBL5211360 0.88 RIPK1 (0.37) RIPK1F2F10ROCK1ALDH1A1
Trifluoroacetic Acid SCHEMBL5216182 0.88 RIPK1 (0.39) RIPK1FOLH1F2F10ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1240154-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
US-7157585-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2007-01-02 US disclosed
US-20050215587-A1 Serine protease inhibitors LIVELY SARAH E 2005-09-29 US disclosed
US-6916957-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2005-07-12 US disclosed
US-20030018059-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-01-23 US disclosed
EP-1240154-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2002-09-18 EP disclosed
WO-2001044226-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215587-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 RIPK1 1724/4885FOLH1 1270/4885F2 69/4885
US-20030018059-A1 Serine protease inhibitors TPSAB1, PRSS1, SERPINB1 RIPK1 1933/4885FOLH1 1449/4885F2 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.